ArticleJACC. Basic to translational science2025
Chemokine Receptor 2 Is a Theranostic Biomarker for Abdominal Aortic Aneurysms.
Article in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Synergistic elastase and papain injury drives abdominal aortic aneurysm formation and rupture in mice.Communications medicine · 2026Article
- Modulation of CCR2/CCL2 molecular axis in the expansion and rupture of abdominal aortic aneurysms.Frontiers in cardiovascular medicine · 2026Review
- Multifunctional nanoparticles in abdominal aortic aneurysm management: from basic research to clinical transformation.Journal of nanobiotechnology · 2025Review
- Emerging PET radiotracers for vascular imaging.Rheumatology (Oxford, England) · 2025Review
- Pilot first-in-human CCR2 PET/CT to detect abdominal aortic aneurysm wall instability.Theranostics · 2025Article
- Targeting monocyte heterogeneity in aortic aneurysms: immunomodulatory strategies and therapeutic opportunities.Frontiers in cardiovascular medicine · 2025Review
- Identification of ARHGAP9 as a Key Diagnostic Marker for Abdominal Aortic Aneurysm by Multiomics and Experimental Validation.Human mutation · 2025Article
- Analysis of small abdominal aortic aneurysms with the radiotracer technetium-99m- 6-hydrazinylnicotinoyl-C-C-chemokine receptor-2 ligand (Polish journal of radiology · 2024Article
Corrections and comments
- Update of
Authors and funding
25 authors.
Funding
Abstract
Abdominal aortic aneurysm (AAA) is a degenerative vascular disease with a high mortality upon rupture. There is no diagnosis to predict the rupture nor effective medical therapies to prevent rupture. Here we demonstrate that the C-C chemokine receptor type 2 (CCR2) is a theranostic biomarker for AAA. In rat AAA models, we determined the potential of a CCR2-targeted positron emission tomography radiotracer [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.